Northern Trust
NVCT icon

Northern Trust’s Nuvectis Pharma NVCT Stock Holding History

Northern Trust’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Buy
146,714
+22,502
+18% +$252K ﹤0.01% 2963
2026
Q1 		$960K Buy
124,212
+7,807
+7% +$66.9K ﹤0.01% 3361
2025
Q4 		$879K Buy
116,405
+9,764
+9% +$63.7K ﹤0.01% 3441
2025
Q3 		$642K Sell
106,641
-3,176
-3% -$21.8K ﹤0.01% 3566
2025
Q2 		$820K Buy
109,817
+71,759
+189% +$651K ﹤0.01% 3485
2025
Q1 		$372K Buy
38,058
+12,333
+48% +$88.8K ﹤0.01% 3691
2024
Q4 		$139K Buy
25,725
+10,472
+69% +$65.6K ﹤0.01% 4088
2024
Q3 		$95.9K Sell
15,253
-34,574
-69% -$227K ﹤0.01% 4068
2024
Q2 		$315K Sell
49,827
-12,270
-20% -$83.4K ﹤0.01% 3679
2024
Q1 		$509K Buy
62,097
+523
+0.8% +$4.45K ﹤0.01% 3559
2023
Q4 		$514K Buy
61,574
+6,887
+13% +$61.4K ﹤0.01% 3530
2023
Q3 		$705K Buy
54,687
+1,053
+2% +$15.3K ﹤0.01% 3406
2023
Q2 		$857K Buy
+53,634
New +$856K ﹤0.01% 3420

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Northern Trust's NVCT Position: Q2 2026 in Review

Northern Trust increased its Nuvectis Pharma (NVCT) stake by 18% in Q2 2026, buying an estimated $252K and bringing the position to 146,714 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

Northern Trust first reported a position in NVCT in Q2 2023 and has held it in 13 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Northern Trust held 146,714 shares of Nuvectis Pharma worth $2.7M as of Q2 2026.
  • Northern Trust bought 22,502 Nuvectis Pharma shares in Q2 2026, an estimated $252K.
  • Nuvectis Pharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2963 holding.
  • Northern Trust first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 13 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.